ReviewTrends in analytical chemistry : TRAC2023
CRISPR-based nucleic acid diagnostics for pathogens.
Review in Trends in analytical chemistry : TRAC, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Advanced integrated SERS-based strategies for the early diagnosis of upper gastrointestinal cancers.Journal of nanobiotechnology · 2026Review
- Rapid On-Site Detection ofFoods (Basel, Switzerland) · 2026Article
- Application of CRISPR/Cas13a system on the rapid detection of Salmonella spp.PLoS neglected tropical diseases · 2026Article
- A CRISPR-Cas13a-Based Amplification- and Extraction-Free Fire Blight Diagnostic System.The plant pathology journal · 2026Article
- One-step detection of Chlamydia psittaci using recombinase polymerase amplification and CRISPR/Cas12b.AMB Express · 2026Article
- Applications and Challenges of CRISPR-Cas Technology for the Detection of Antimicrobial Resistance Genes.Infection and drug resistance · 2026Review
- Proteomics in the Diagnosis of Viral and Pathogenic Infections.Advances in experimental medicine and biology · 2026Review
- Point-of-care molecular diagnostics and drug-resistance mechanisms in neglected infectious diseases: current advances and future therapeutic opportunities.Frontiers in cellular and infection microbiology · 2026Review
- Diagnostic Approaches for Measles Virus: Methods, Advances, and Ongoing Challenges.Pathogens (Basel, Switzerland) · 2025Review
- CRISPR Technology: Transforming the Future of Medicine and Diagnostics.Biochemistry · 2025Review
- CRISPR Genome Editing in Personalized Therapy for Oral and Maxillofacial Diseases: A Scoping Review.Biomedicines · 2025Review
- Modular and signal-responsive transcriptional regulation using CRISPRi-aided genetic switches in Escherichia coli.Journal of biological engineering · 2025Article
- Rapid Amplification and Detection of Single-Stranded Nucleic Acids for Point-of-Care Diagnosis.Small methods · 2025Review
- New frontiers in CRISPR: Addressing antimicrobial resistance with Cas9, Cas12, Cas13, and Cas14.Heliyon · 2025Review
- CRISPR/Cas system and its application in the diagnosis of animal infectious diseases.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024Review
- A Novel High-Throughput Sample-in-Result-Out Device for the Rapid Detection of Viral Nucleic Acids.Biosensors · 2024Article
- Iterative crRNA design and a PAM-free strategy enabled an ultra-specific RPA-CRISPR/Cas12a detection platform.Communications biology · 2024Article
- Point-of-care testing ofHeliyon · 2024Article
- One-Tube Nested PCR Coupled with CRISPR-Cas12a for Ultrasensitive Nucleic Acid Testing.ACS omega · 2024Article
- Repurposing Type I-A CRISPR-Cas3 for a robust diagnosis of human papillomavirus (HPV).Communications biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pathogenic infection remains the primary threat to human health, such as the global COVID-19 pandemic. It is important to develop rapid, sensitive and multiplexed tools for detecting pathogens and their mutated variants, particularly the tailor-made strategies for point-of-care diagnosis allowing for use in resource-constrained settings. The rapidly evolving CRISPR/Cas systems have provided a powerful toolbox for pathogenic diagnostics via nucleic acid tests. In this review, we firstly describe the resultant promising class 2 (single, multidomain effector) and recently explored class 1 (multisubunit effector complexes) CRISPR tools. We present diverse engineering nucleic acid diagnostics based on CRISPR/Cas systems for pathogenic viruses, bacteria and fungi, and highlight the application for detecting viral variants and drug-resistant bacteria enabled by CRISPR-based mutation profiling. Finally, we discuss the challenges involved in on-site diagnostic assays and present emerging CRISPR systems and CRISPR cascade that potentially enable multiplexed and preamplification-free pathogenic diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.